Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations

International Journal of Pharmaceutics

Volumn 186, Issue 2, 1999, Pages 169-175

  Perkins, A C ^a   Wilson, C G ^b   Frier, M ^a   Vincent, R M ^a   Blackshaw, P E ^a   Dansereau, R J ^c   Juhlin, K D ^c   Bekker, P J ^c   Spiller, R C ^d  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^c PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

^d NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Esophageal transit; Risedronate; Tablet formulations

Indexed keywords

CELLULOSE; GELATIN; RISEDRONIC ACID;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CAPSULE; DRUG FORMULATION; DRUG TRANSPORT; ESOPHAGUS; FILM COATING; GAMMA SCINTIGRAPHY; HUMAN; HUMAN EXPERIMENT; INTESTINE TRANSIT TIME; NORMAL HUMAN; OSTEOPOROSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET;

EID: 0032886956     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00172-6     Document Type: Article

References (34)

1. Applegate G.R., Malmud L.S., Rock E., Reilley J.R., Fisher R.S. It's a hard pill to swallow or don't take it lying down. Gastroenterology. 78:1980;1132.
2. Bailey R.T.J., Bonavina L., McChesney L., Spires K.J., Muilenburg M.I., McGill J.E., DeMeester T.R. Factors influencing the transit of a gelatin capsule in the esophagus. Drug. Intell. Clin. Pharm. 21:1987;282-285.
3. Blackwell J.N., Hannan W.J., Adam R.D., Heading R.C. Radionuclide transit studies in the detection of oesophageal dysmotility. Gut. 24:1983;421-426.
4. Castell D.O. Esophageal disorders in the elderly. Gastroenterol. Clin. North Am. 19:1990;235-254.
5. Channer K.S., Virjee J.P. The effect of formulation on oesophageal transit. J. Pharm. Pharmacol. 37:1985;126-129.
6. Channer K.S., Virjee J.P. The effect of size and shape of tablets on their esophageal transit. J. Clin. Pharmacol. 26:1986;141-146.
7. Coleman R., Houston S., Rubens R., Leonard R., Rodger A. Evaluation of the acute toxicity and efficacy of a new oral formulation of pamidronate. Br. J. Cancer. 63(Suppl. 13):1991;11.
8. Eastell, R., Minne, H., Sorensen, O., Hooper, M., Ritter-Hrncrick, C., Pack, S., Roumagnac, I., Ethgen, D., Reginster, J.Y., 1999. Risedronate reduces fracture risk in women with established postmenopausal osteoporosis. Calcif. Tissue. Int. 64 (1) 543.
9. Ekberg O., Feinberg M.J. Altered swallowing function in elderly patients without dysphagia: radiologic findings in 56 cases. Am. J. Roentgenol. 156:1991;1181-1184.
10. Eng J., Sabanathan S. Drug-induced esophagitis. Am. J. Gastroenterol. 86:1991;1127-1133.
11. Evans K.T., Roberts G.M. Where do all the tablets go? Lancet. 2:1976;1237-1239.
12. Gallo S.H., McClave S.A., Makk L.J., Looney S.W. Standardization of clinical criteria required for use of the 12.5 millimeter barium tablet in evaluating esophageal lumenal patency. Gastrointest. Endosc. 44:1996;181-184.
13. Ham H.R., Georges B., Guillaume M., Erbsmann F., Dobbeleir A. Evaluation of methods for qualitative and quantitative assessment of esophageal transit of liquid. Eur. J. Nucl. Med. 11:1985;17-21.
14. Holloway R.H., Lange R.C., Plankey M.W., McCallum R.W. Detection of esophageal motor disorders by radionuclide transit studies: a reappraisal. Dig. Dis. Sci. 34:1989;905-912.
15. Jorgensen F., Hesse B., Tromholt N., Hojgaard L., Stubgaard M. Esophageal scintigraphy: reproducibility and normal ranges. J. Nucl. Med. 33:1992;2106-2109.
16. Kahrilas P.J., Dodds W.J., Hogan W.J. Effect of peristaltic dysfunction on esophageal volume clearance. Gastroenterology. 94:1988;73-80.
17. Kazem I. A new scintigraphic technique for the study of the esophagus. Am. J. Roentgenol. 115:1972;681-687.
18. Kikendall J.W., Friedman A.C., Oyewole M.A., Fleischer D., Johnson L.F. Pill-induced esophageal injury: case reports and review of medical literature. Dig. Dis. Sci. 28:1983;174-182.
19. Kjellen G., Svedberg J.B., Tibbling L. Solid bolus transit by esophageal scintigraphy in patients with dysphagia and normal manometry and radiography. Dig. Dis. Sci. 29:1984;1-5.
20. Klein H.A. Esophageal transit scintigraphy. Semin. Nucl. Med. 25:1995;306-317.
21. Klein H.A., Wald A. Computer analysis of radionuclide esophageal transit studies. J. Nucl. Med. 25:1984;957-964.
22. Lehmann E.L. Testing Statistical Hypotheses. 1959;Wiley, New York.
23. Lufkin E.G., Argueta R., Whitaker M.D., Cameron A.L., Wong V.H., Egan K.S., O'Fallon W.M., Riggs B.L. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos. Int. 4:1994;320-322.
24. Mughal M.M., Marples M., Bancewicz J. Scintigraphic assessment of oesophageal motility: what does it show and how reliable is it? Gut. 27:1986;946-953.
25. Pemberton J. Oesophageal obstruction and ulceration caused by oral potassium therapy. Br. Heart J. 32:1970;267-268.
26. Perkins A.C., Wilson C.G., Blackshaw P.E., Vincent R.M., Dansereau R.J., Juhlin K.D., Bekker P.J., Spiller R.C. Impaired oesophageal transit of capsule versus tablet formulations in the elderly. Gut. 35:1994;1363-1367.
27. Perlman A.L., Schultz J.G., VanDaele D.J. Effects of age, gender, bolus volume and bolus viscosity on oropharyngeal pressure during swallowing. J. Appl. Physiol. 75:1993;33-37.
28. Russell C.O., Hill L.D., Holmes III E.R., Hull D.A., Gannon R., Pope C.E. Radionuclide transit: a sensitive screening test for esophageal dysfunction. Gastroenterology. 80:1981;887-892.
29. Sand A., Ham H., Piepsz A. Oesophageal transit patterns in healthy subjects. Nucl. Med. Commun. 7:1986;741-745.
30. Santucci L., Patoia L., Fiorucci S., Farromi F., Favero D., Morelli A. Oesophageal lesions during treatment with piroxicam. Br. Med. J. 300:1990;1018.
31. Svedberg J.B. The bolus transport diagram: a functional display method applied to oesophageal studies. Clin. Phys. Physiol. Meas. 3:1982;267-272.
32. Tolin R.D., Malmud L.S., Reilley J., Fisher R.S. Esophageal scintigraphy to quantitate esophageal transit. Gastroenterology. 76:1979;1402-1408.
33. Wamberg T., Jorgensen F., Hasselbalch H., Hey H. The prejudgment of the oesophageal transfer of tablets and capsules. Arch. Pharm. Chem. Sci. Ed. 11:1983;24-31.
34. Watts, N., Hangartner, T., Chesnut, C., Genant, H., Miller, P., Eriksen, E., Chines, A., Axelrod, D., McKeever, C., 1999. Risedronate treatment prevents vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. Calcif. Tissue. Int. 64 (1).